Venn Life Sciences Holdings PLC Acquisition of Minority Interest (5893C)

TIDMVENN

RNS Number : 5893C

Venn Life Sciences Holdings PLC

23 January 2018

23 January 2018

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Acquisition of Minority Interest

Venn Life Sciences Holdings PLC ("VLS"), today announces that it has reached agreement with Christian Le Bras ("CLB") to acquire the 11.03% interest in Venn Life Sciences France S.A.S. ("VLSF") that it does not already own. The agreed offer price per share is EUR29.04 representing a total consideration of EUR34,330 to be settled by the issue of 277,550 ordinary shares in VLS or 0.5% of VLS's current issued capital based on VLS's current share price of GBP0.11 (EUR0.1237 at a GBPEUR exchange rate of 0.8893 for 22 January 2018). Following this, VLS will have 100% ownership of VLSF and have 60,561,813 ordinary shares in issue. CLB will retain his role as Head of Interactive Response Technology in VLS.

VLSF is the sole French operating entity of VLS conducting the full range of Clinical Services and as at 30 June 2016 had net liabilities of EUR159,000 and retained P&L deficit of EUR310,000. VLS acquired its majority shareholding in VLSF in 2014.

The Independent Directors, being Allan Wood, Jonathan Hartshorn, Christian Milla, Michael Ryan and Mary Sheahan, who are not related parties under the AIM Rules and ESM Rules for the purpose of the investment, having consulted with Davy, the company's NOMAD and ESM adviser, for the purpose of the AIM Rules and ESM Rules, consider that the investment is fair and reasonable insofar as the shareholders of the company are concerned. As a non-executive director of VLSF Anthony Richardson has not taken part in the Board's consideration of these matters.

Enquiries:

 
 
  Venn Life Sciences Holdings Plc 
Allan Wood, Non-Executive Chairman 
Tony Richardson, Chief Executive Officer                    Tel: [phone] 
 
Davy (Nominated Adviser and Broker) 
Fergal Meegan / Matthew de Vere                            Tel: [phone] 
 White (Corporate Finance) 
Orla Bolger (Corporate Broking) 
 
Hybridan LLP (Co-Broker)                               Tel: [phone] 
Claire Louise Noyce 
 
Walbrook PR Ltd                                         Tel: [phone] 
 
 
 
 

About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences www.vennlifesciences.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQBTMRTMBATBAP

(END) Dow Jones Newswires

January 23, 2018 02:00 ET (07:00 GMT)